Trial Profile

A Phase 1/2A, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HT31-1 (hCitH3-mAb) in Healthy Volunteers and in Patients With Mild-to-Moderate ARDS: Part A (Healthy Volunteers)

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

13 Mar 2026 New trial record
10 Jan 2026 According to HTIC Inc media release,this trial has begun evaluating hCitH3-mAb, a novel monoclonal antibody therapy targeting sepsis-induced acute respiratory distress syndrome (ARDS).
10 Jan 2026 According to HTIC, Inc media release, the current Phase 1a study is designed to assess safety in healthy volunteers,will be led by Dr. Alpha Fowler,and Dr. Imre Noth will co-lead the multicenter Phase 2a trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com